COLLAGEN XIII-DEPENDENT MYASTHENIAS – MECHANISMS AND THERAPEUTIC PROSPECTS

Description of the granted funding

We address the roles and molecular interactions of collagen XIII (ColXIII) in the neuromuscular junction (NMJ). We have shown that ColXIII is an essential NMJ component and others have recently shown that mutations in the human gene cause congenital myasthenic syndrome type 19 (CMS19). Using mouse and cell culture models we will identify the network of molecules and the events whereby ColXIII operates in the normal NMJ and the developmental events that lead to CMS19. We will also determine the occurrence of anti-ColXIII autoimmuneantibodies in patients with acquired generalized and ocular myasthenia gravis and assess their effects on the NMJ. The research is performed at the Faculty of Biochemistry and Molecular Medicine, University of Oulu. The studies provide unique opportunities to enhance the understanding of critical motor synapse molecules and facilitate personalized therapies in genetic and acquired myasthenia. See (https://www.oulu.fi/university/researcher/taina-pihlajaniemi).
Show more

Starting year

2021

End year

2025

Granted funding

Taina Pihlajaniemi Orcid -palvelun logo
474 045 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

341776

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

genes, genetics